• Good Clinical Practice, Basic - Barbara Penningtion

Overview of the MedDRA Coding System 

• Introduction to MedDRA  - Kathy Huntley 

• MedDRA Guidelines - Wendy Brown

QA/QC, Site and Study Coordinators Training 

• Protocol Registration Requirements - Daniel Molina

• Monitoring Visits: Before, During, and After - Kandrea Collins; Suzanne Olsen

• CRF Tracking System - Len Quiat

• Invitation to DRATS; Data Return to Sites - Matthew Baldwin

• SCHARP's Role in Safety Monitoring and Reporting - Wendy Brown; Molly Swenson

• Release of HPTN Data from the SDMC - Lynda Emel

• HIV Endpoint Determination - Anne Coletti

Laboratory Training

• Stay on Track with Internal Laboratory QC

• Using Proficiency Testing to Improve Lab Performance

• Site Presentations

  • Belo Horizonte, Brazil 

  • Porto Alegre, Brazil 

  • Rio de Janeiro, Brazil

  • Guangxi and Xinjiang, China

  • Pune, India 

  • Lilongwe, Malawi

  • Blantyre, Malawi

  • Lima, Peru

  • Durban, South Africa

  • Dar es Salaam, Tanzania

  • Chiang Mai, Thailand

  • Kampala, Uganda

  • Lusaka, Zambia 

  • Harare, Zimbabwe

Welcome

• State of the Network - Ward Cates

• HIV Prevention Research: Now More than Ever - Jessie Mbwambo

Session I: What Have We Learned from HIVNET/HPTN Trials

• Effectiveness of Repeat Single-dose Nevirapine in Subsequent Pregnancies Among Ugandan Women - Francis Mmiro

• Five Year Growth Patterns of HIV Infected and Uninfected Children in HIVNET 012 - Laura Guay

• Prevalence and Incidence of Pharyngeal Gonorrhea in EXPLORE MSM - Susan Buchbinder

• Herpes Simplex Virus Type 2 HSV-2) Acquisition Among Men Who Have Sex with men (MSM): Effect on HIV Acquisition and Effect of EXPLORE Behavioral Intervention - Connie Celum

• Microbicide Site Preparedness Study - HPTN 055 - Gita Ramjee

• Characterization of Baseline Mucosal Indices of Injury and Inflammation in Men for Use in Rectal Microbicide Trials - Ian McGowan

• Safety and Tolerability of Vaginal Tenofovir Gel in HIV- and HIV+ Women: Lessons Learned - Ken Mayer

Session II: Achievements, Lessons Learned, and Future Challenges of Ongoing HPTN Trials

• HPTN 039: Acyclovir suppression to prevent HIV acquisition - Connie Celum

• HPTN 035: One year post-initiation: Progress and Challenges - Salim Abdool Karim

• HPTN 037 Implementation: A phase III randomized study to evaluate the efficacy of a network-oriented peer education intervention for the prevention of HIV transmission among injection drug users and their network members - Apinun Aramrattna

• HPTN 052: A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy plus HIV Primary Care versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 In Serodiscordant Couples - Myron Cohen

• Retention Under Challenging Circumstances in Zimbabwe - Frances Cowan

Session III: Community Based Activities: Lessons Learned

• Best Practices for Community Representative Involvement in HIV Clinical Research Networks - John Mutsambi; Monica Ruiz

• NIMH Project Accept/HPTN 043: Community-Based Voluntary Counseling and Testing (VCT) - David Celentano

• Community Involvement in International Research: Lessons Learned from the HPTN and the Peru Case Study - Jeff Stanton; Pedro Goicochea

• Will a Pill a Day Prevent HIV? Anticipating the Results of the Tenofovir "PREP" Trials - Mitchell Warren

• Microbicides Research Agenda - Sharon Hillier

• Antiretroviral, Behavioral, Substance Use and STD Control Research Agenda - Sten Vermund

• Pediatric Research Agenda - Brooks Jackson

• DAIDS Enterprise System, Presentation and Q&A - Jonathan Kagan; Hemant Virkar

• Closing Plenary: NIAID, the HPTN, and Beyond - Tony Fauci